TY - JOUR
T1 - The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma
AU - Karantanis, Dimitrios
AU - Subramaniam, Rathan M.
AU - Peller, Patrick J.
AU - Lowe, Val J.
AU - Durski, Jolanta M.
AU - Collins, Douglas A.
AU - Georgiou, Evangelos
AU - Ansell, Stephen M.
AU - Wiseman, Gregory A.
PY - 2008/4
Y1 - 2008/4
N2 - Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.
AB - Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.
KW - FDG uptake
KW - Nasal lesions
KW - Neck nodes
KW - Paranasal lesions
UR - http://www.scopus.com/inward/record.url?scp=44649171004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44649171004&partnerID=8YFLogxK
U2 - 10.3816/CLM.2008.n.010
DO - 10.3816/CLM.2008.n.010
M3 - Article
C2 - 18501102
AN - SCOPUS:44649171004
SN - 2152-2669
VL - 8
SP - 94
EP - 99
JO - Clinical Lymphoma
JF - Clinical Lymphoma
IS - 2
ER -